NCT07126158 2026-04-15
Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
Washington University School of Medicine
Phase 2 Recruiting
Clinical Trials
6 trialsNCT02465060 2026-04-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06495125 2026-04-06
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
Emory University
Phase 2 Recruiting
NCT06369259 2026-04-01
Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06007924 2026-03-27
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT04331041 2026-03-25
Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
Washington University School of Medicine
Phase 2 Active not recruiting